Idrinol solution 100mg/ml 5ml #5

Idrinol solution instruction

You can buy Idrinol solution here

Release form, composition and packaging

The solution for IV, IM and parabulbar injection is transparent, colorless.
1 amp
Meldonium dihydrate 500 mg,
which corresponds to the content of Meldonium 401.05 mg
Excipients: water d / and - up to 5 ml.

pharmachologic effect

Meldonium is a structural analogue of gamma-butyrobetaine - a substance that is present in every cell of the human body.
Meldonium inhibits gamma-butyrobetaine hydroxygene, reduces carnitine synthesis and transport of long-chain fatty acids through cell walls, prevents accumulation of activated forms of unoxidized fatty acids - acylcarnitine and acylcoenzyme A. adenosine triphosphate acid (ATP) transport. At the same time, it activates glycolysis, which flows without additional consumption of oxygen. As a result of reducing the concentration of carnitine, gamma-butyrobetaine with vasodilating properties is intensively synthesized. The mechanism of action determines the diversity of its pharmacological effects: increased efficiency, reduced symptoms of mental and physical overstrain, activation of tissue and humoral immunity, cardioprotective action.
In the case of acute ischemic myocardial damage, it slows down the formation of a zone of necrosis, shortens the rehabilitation period. In heart failure, it improves myocardial contractility, increases exercise tolerance, and reduces the frequency of strokes. In acute and chronic ischemic disorders of cerebral circulation improves blood circulation in the ischemic focus.
Effective in the case of vascular pathology of the fundus.
Idrinol solution eliminates functional disorders of the nervous system in patients with chronic alcoholism during abstinence.

Pharmacokinetics

Cmax in plasma is achieved immediately after administration. Metabolized in the body to form two major metabolites that are excreted by the kidneys. T1 / 2 is 3-6 hours.

Indications

- as part of a complex treatment of coronary artery disease (angina, myocardial infarction); chronic heart failure, dyshormonal cardiomyopathy;
- as part of the treatment of acute cerebrovascular accident (ischemic stroke, cerebrovascular insufficiency);
- reduced performance; physical strain (including athletes);
- withdrawal syndrome in chronic alcoholism (in combination with specific therapy);
- hemophthalmus and retinal hemorrhage of various etiologies, thrombosis of the central vein of the retina and its branches, retinopathy of various etiologies (diabetic, hypertensive).

Contraindications for Idrinol solution

- hypersensitivity to Idrinol solution;
- increased intracranial pressure (in violation of venous outflow and intracranial tumors);
- age up to 18 years (efficacy and safety have not been established).
With care: diseases of the liver and / or kidneys.

Dosage

In connection with the possibility of the development of a stimulating effect, the drug is recommended to be used in the first half of the day.
Idrinol solution is used in / in, in / m and parabulbarno.
The route of administration, dose and duration of treatment set individually, depending on the evidence, the severity of the condition.

Cardiovascular diseases

In the complex therapy:
IHD (myocardial infarction) - in / in the jet of 500-1000 mg / day, applying the entire dose at once or dividing it into 2 administrations;
IHD (stable angina), chronic heart failure and dyshormonal cardiomyopathy - intravenously in a dose of 500-1000 mg / day, using the entire dose at one time or dividing it into 2 doses, or intramuscularly 500 mg 1-2 times a day.
The course of treatment is 10-14 days, with the possible subsequent transition to the intake of Meldonium. The maximum course of treatment is 4-6 weeks.

Disorders of cerebral circulation

As part of complex therapy in the acute phase of 500 mg 1 time / day in / in for 10 days, with the possible subsequent transition to the reception of meldonium inside 500-1000 mg. The maximum course of treatment is 4-6 weeks.
In chronic cerebral circulatory insufficiency (dyscirculatory encephalopathy), 500 mg i / m or v / v 1 time / day for 10 days, then with a possible subsequent transition to receive meldonium with 500 mg orally. The maximum course of treatment is 4-6 weeks. Repeated courses are conducted on the recommendation of a doctor (usually 2-3 times a year).
Ophthalmopathology (hemophthalmus and retinal hemorrhages of various etiologies, thrombosis of the central vein of the retina and its branches, retinopathy of various etiologies (diabetic, hypertensive))
Idrinol solution is administered parabulbarno 50 mg for 10 days, including as part of combination therapy.

Mental and physical overload

At 500 mg / m and / in 1 time / day. The course of treatment is 10-14 days. If necessary, the treatment is repeated after 2-3 weeks.

Chronic alcoholism

At 500 mg / m or / 2 times / day. The course of treatment is 7-10 days.

Side effects

Since the cardiovascular system: rarely - tachycardia, decrease or increase in blood pressure.
From the side of the central nervous system: rarely - psychomotor agitation.
On the part of the digestive system: rarely - dyspeptic disorders.
Allergic reactions: rarely - pruritus, rash, hyperemia of the skin, angioedema; very rarely - eosinophilia.
Other: very rarely - general weakness.

Overdose

Symptoms: decrease in blood pressure, accompanied by headache, tachycardia, dizziness and general weakness.
Treatment: symptomatic.

Drug interaction

Can be combined with antianginal agents, anticoagulants, antiplatelet agents, antiarrhythmic agents, diuretics, bronchodilators.
Enhances the action of cardiac glycosides.
Due to the possible development of moderate tachycardia and hypotension, caution should be exercised when combined with nitroglycerin, nifedipine, alpha-blockers, antihypertensives and peripheral vasodilators.

special instructions

Idrinol solution is not a first-line drug for acute coronary syndrome.
Influence on ability to drive vehicles and mechanisms
Data on the adverse effects of the drug Idrinol solution on the speed of psychomotor reactions is not available.

Pregnancy and lactation

The safety of Idrinol solution during pregnancy is not proven. In order to avoid possible adverse effects on the fetus should not be prescribed the drug during pregnancy.
It is not known whether Idrinol solution is excreted in breast milk. If necessary, the use of the drug Idrinol solution during lactation breastfeeding should be stopped.

Use in childhood

Contraindication: age up to 18 years (efficacy and safety have not been established).

In case of impaired renal function

With care: kidney disease.

With abnormal liver function

With care: liver disease.

Pharmacy sales terms

The prescription is not required to buy Idrinol solution.

Terms and conditions of storage

The drug should be stored out of the reach of children at a temperature not higher than 25 ° C. Do not freeze. Shelf life - 5 years.